A comparative trial of remission induction (by cytosine arabinoside, or C.A.R. and thioguanine, or C.A.R. and daunorubicine) and maintenance therapy (by C.A.R. or methylgag) in acute myeloid leukaemia.
D000293:Adolescent; D000328:Adult; D000368:Aged; D000578:Amidines / Q000008:administration & dosage* / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000008:administration & dosage* / Q000627:therapeutic use; D002648:Child; D003561:Cytarabine / Q000008:administration & dosage* / Q000627:therapeutic use; D003630:Daunorubicin / Q000008:administration & dosage* / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D005069:Evaluation Studies as Topic; D006037:Glyoxal / Q000008:administration & dosage / Q000627:therapeutic use; D006801:Humans; D006835:Hydrazones / Q000008:administration & dosage / Q000627:therapeutic use; D015470:Leukemia, Myeloid, Acute / Q000188:drug therapy*; D008875:Middle Aged; D012075:Remission, Spontaneous; D013866:Thioguanine / Q000008:administration & dosage* / Q000627:therapeutic use
D000578:Amidines; D000970:Antineoplastic Agents; D006835:Hydrazones; D003561:Cytarabine; D006037:Glyoxal; D013866:Thioguanine; D003630:Daunorubicin